

Pirkko Mattila

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5144095/publications.pdf>

Version: 2024-02-01

14
papers

640
citations

1162889

8
h-index

1125617

13
g-index

17
all docs

17
docs citations

17
times ranked

1623
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel variant in SMG9 causes intellectual disability, confirming a role for nonsense-mediated decay components in neurocognitive development. <i>European Journal of Human Genetics</i> , 2022, 30, 619-627.	1.4	6
2	Analysis of human brain tissue derived from DBS surgery. <i>Translational Neurodegeneration</i> , 2022, 11, 22.	3.6	3
3	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. <i>Science Advances</i> , 2021, 7, .	4.7	28
4	Immunogenomic Landscape of Hematological Malignancies. <i>Cancer Cell</i> , 2020, 38, 380-399.e13.	7.7	109
5	Birch pollen allergen immunotherapy reprograms nasal epithelial transcriptome and recovers microbial diversity. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2293-2296.e11.	1.5	11
6	Absence of NEFL in patient-specific neurons in early-onset Charcot-Marie-Tooth neuropathy. <i>Neurology: Genetics</i> , 2018, 4, e244.	0.9	25
7	Genetic Control of Myelin Plasticity after Chronic Psychosocial Stress. <i>ENeuro</i> , 2018, 5, ENEURO.0166-18.2018.	0.9	48
8	The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. <i>BMC Genomics</i> , 2017, 18, 629.	1.2	42
9	Complete Genome Sequences of Influenza A/H1N1 Strains Isolated from Patients during the 2013-2014 Epidemic Season in Finland. <i>Genome Announcements</i> , 2015, 3, .	0.8	3
10	The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies. <i>Blood</i> , 2014, 124, 2203-2203.	0.6	3
11	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429.	7.7	334
12	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. <i>Blood</i> , 2013, 122, 482-482.	0.6	0
13	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. <i>Blood</i> , 2012, 120, 288-288.	0.6	1
14	Cloning and expression of <i>Helicobacter pylori</i> GDP-I -fucose synthesizing enzymes (GMD and GMER) in <i>Saccharomyces cerevisiae</i> . <i>FEBS Journal</i> , 2001, 268, 6458-6464.	0.2	27